DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

Core Insights - DSS, Inc. has sold its Celios® air purification asset to Impact BioMedical Inc. for approximately $1.15 million in an all-equity transaction, aligning with its strategy to optimize its portfolio and focus on core growth areas [1][3] - The Celios® technology features a patented three-stage filtration system that removes ultrafine particles as small as 10 nanometers, enhancing indoor air quality and reducing airborne health risks [2][5] - The CEO of DSS, Inc. stated that the sale is part of a strategic effort to streamline holdings and concentrate on key business objectives, allowing Impact BioMedical to leverage the technology effectively [3] Company Overview - DSS, Inc. operates across multiple high-growth sectors, focusing on creating, acquiring, and investing in innovative companies that provide sustainable value for shareholders [4] - Celios® is dedicated to improving indoor air quality through advanced filtration solutions, designed for efficiency and portability, meeting high standards of cleanliness and safety [5]